Giuseppe Barbesino, MD

Articles by Giuseppe Barbesino, MD

Novel Treatment Advances in Differentiated Thyroid Cancer

ByLori J. Wirth, MD,Marcia Brose, MD, PhD, FASCO,Naifa L. Busaidy, MD, FACP, FACE,Maria E. Cabanillas, MD,Giuseppe Barbesino, MD

February 3rd 2022

An overview of therapies in the pipeline for differentiated thyroid cancer and their potential effect on clinical decision-making.

BRAF Inhibitors and Immunotherapy for Differentiated Thyroid Cancer

ByLori J. Wirth, MD,Maria E. Cabanillas, MD,Giuseppe Barbesino, MD

February 3rd 2022

The role of BRAF inhibitors and checkpoint inhibitors in differentiated thyroid cancer, and potential considerations for using BRAF inhibition as redifferentiation therapy.

Giuseppe Barbesino, MD

Articles by Giuseppe Barbesino, MD

Novel Treatment Advances in Differentiated Thyroid Cancer

BRAF Inhibitors and Immunotherapy for Differentiated Thyroid Cancer

Latest Updated Articles

Trending on OncLive

Lurbinectedin-Based Triplet Shows Clinical Benefit in Advanced Soft Tissue Sarcoma

Ultra-Sensitive ctDNA and CSF Liquid Biopsy May Refine Monitoring and Adaptive Trial Designs in Metastatic Breast Cancer

Anti–Gremlin-1 Therapy Plus Chemo Makes Waves in GI Malignancies

Nuvisertib Yields Strong Safety, Promising Efficacy in R/R Myelofibrosis

FDA Approves Larger Vial Size for Nelarabine Injection in T-ALL and T-LBL